You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclizine
Accession NumberDB01176  (APRD00061)
TypeSmall Molecule
GroupsApproved
DescriptionA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Structure
Thumb
Synonyms
(+-)-1-Diphenylmethyl-4-methylpiperazine
(±)-1-diphenylmethyl-4-methylpiperazine
(N-Benzhydryl)(n'-methyl)diethylenediamine
1-(Diphenylmethyl)-4-methylpiperazine
1-Benzhydryl-4-methylpiperazin
Ciclizina
Cyclizine
Cyclizinum
N-Benzhydryl-N'-methylpiperazine
N-methyl-N'-benzhydrylpiperazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Marzine Inj 50mg/mlliquid50 mgintramuscular; intravenousGlaxo Wellcome Inc.1988-12-311998-07-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cycliverttablet25 mg/25mgoralLaser Pharmaceuticals, LLC2011-11-01Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
EmoquilNot Available
MarezineNot Available
MarzineGlaxoSmithKline
ValoidGlaxoSmithKline
Brand mixtures
NameLabellerIngredients
Megral TabsGlaxo Wellcome Inc.
Salts
Name/CASStructureProperties
Cyclizine chloride
Thumb
  • InChI Key: UKPBEPCQTDRZSE-UHFFFAOYSA-N
  • Monoisotopic Mass: 302.154976453
  • Average Mass: 302.842
DBSALT000399
Cyclizine hydrochloride
ThumbNot applicableDBSALT001535
Cyclizine lactate
ThumbNot applicableDBSALT001182
Categories
UNIIQRW9FCR9P2
CAS number82-92-8
WeightAverage: 266.3807
Monoisotopic: 266.178298714
Chemical FormulaC18H22N2
InChI KeyInChIKey=UVKZSORBKUEBAZ-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3
IUPAC Name
1-(diphenylmethyl)-4-methylpiperazine
SMILES
CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Piperazine
  • 1,4-diazinane
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo (dizziness caused by other medical problems).
PharmacodynamicsCyclizine is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Cyclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which cyclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects.
Mechanism of actionVomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of cyclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since cyclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Cyclizine is metabolised to its N-demethylated derivative, norcyclizine, which has little antihistaminic (H1) activity compared to Cyclizine.

Route of eliminationNot Available
Half life20 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9674
Blood Brain Barrier+0.9813
Caco-2 permeable+0.8023
P-glycoprotein substrateSubstrate0.8071
P-glycoprotein inhibitor INon-inhibitor0.7583
P-glycoprotein inhibitor IINon-inhibitor0.981
Renal organic cation transporterInhibitor0.7875
CYP450 2C9 substrateNon-substrate0.829
CYP450 2D6 substrateSubstrate0.6312
CYP450 3A4 substrateNon-substrate0.6591
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9676
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9071
Ames testNon AMES toxic0.9308
CarcinogenicityNon-carcinogens0.9667
BiodegradationNot ready biodegradable0.983
Rat acute toxicity2.3937 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6672
hERG inhibition (predictor II)Non-inhibitor0.5073
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral25 mg/25mg
Liquidintramuscular; intravenous50 mg
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105.5-107.5Baltzly, R. and Castillo, J.C.; U.S. Patent 2,630,435; March 3,1953; assigned to Burroughs Wellcome & Co. (U.S.A.) Inc.
water solubility1000 mg/L (at 25 °C)MERCK INDEX (1996); less than
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0752 mg/mLALOGPS
logP3.55ALOGPS
logP3.55ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)8.51ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity84.93 m3·mol-1ChemAxon
Polarizability31.53 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Baltzly, R. and Castillo, J.C.; U.S. Patent 2,630,435; March 3,1953; assigned to Burroughs
Wellcome & Co. (U.S.A.) Inc.

General ReferencesNot Available
External Links
ATC CodesR06AE03R06AE53
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyclizine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Cyclizine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cyclizine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Cyclizine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyclizine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Cyclizine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyclizine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cyclizine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclizine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cyclizine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclizine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyclizine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclizine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyclizine.
AmoxapineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Cyclizine.
AmphetamineAmphetamine may decrease the sedative activities of Cyclizine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclizine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Cyclizine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyclizine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Cyclizine.
AzelastineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyclizine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Cyclizine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Cyclizine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Cyclizine.
BenzphetamineBenzphetamine may decrease the sedative activities of Cyclizine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cyclizine.
Benzylpenicilloyl PolylysineCyclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cyclizine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyclizine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
BrimonidineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyclizine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Cyclizine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Cyclizine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclizine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclizine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclizine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclizine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Cyclizine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Cyclizine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Cyclizine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Cyclizine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclizine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyclizine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Cyclizine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cyclizine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclizine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyclizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyclizine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclizine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Cyclizine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyclizine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclizine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Cyclizine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyclizine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyclizine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyclizine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyclizine.
CitalopramThe risk or severity of adverse effects can be increased when Cyclizine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cyclizine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Cyclizine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Cyclizine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Cyclizine.
ClomipramineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Cyclizine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclizine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclizine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyclizine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyclizine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclizine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Cyclizine.
DantroleneThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclizine.
DapoxetineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Cyclizine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyclizine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cyclizine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclizine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Cyclizine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyclizine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Cyclizine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclizine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclizine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cyclizine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclizine.
DifenoxinThe risk or severity of adverse effects can be increased when Cyclizine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclizine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclizine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclizine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclizine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclizine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclizine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Cyclizine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Cyclizine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
DoxylamineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclizine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Cyclizine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Cyclizine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclizine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Cyclizine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Cyclizine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Cyclizine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cyclizine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Cyclizine.
EscitalopramThe risk or severity of adverse effects can be increased when Cyclizine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Cyclizine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclizine.
EthanolCyclizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Cyclizine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclizine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclizine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cyclizine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyclizine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cyclizine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclizine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Cyclizine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Cyclizine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Cyclizine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclizine.
EtoperidoneThe risk or severity of adverse effects can be increased when Cyclizine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyclizine.
EzogabineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Cyclizine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyclizine.
FenfluramineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclizine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Cyclizine.
FlibanserinThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclizine.
FlunarizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cyclizine.
FluoxetineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclizine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclizine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclizine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclizine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Cyclizine.
FluvoxamineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cyclizine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclizine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cyclizine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Cyclizine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Cyclizine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclizine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cyclizine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclizine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Cyclizine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cyclizine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyclizine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclizine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclizine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Cyclizine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
HydroxyzineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Cyclizine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclizine.
IndalpineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclizine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclizine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyclizine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclizine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclizine.
LevetiracetamThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Cyclizine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Cyclizine.
LevocetirizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclizine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclizine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cyclizine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Cyclizine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Cyclizine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cyclizine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Cyclizine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclizine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclizine.
Lu AA21004The risk or severity of adverse effects can be increased when Cyclizine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cyclizine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclizine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Cyclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Cyclizine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Cyclizine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Cyclizine.
MephentermineMephentermine may decrease the sedative activities of Cyclizine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyclizine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclizine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyclizine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclizine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclizine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cyclizine.
MethamphetamineMethamphetamine may decrease the sedative activities of Cyclizine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyclizine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cyclizine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclizine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyclizine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Cyclizine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyclizine.
MethsuximideThe risk or severity of adverse effects can be increased when Cyclizine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyclizine.
MetyrosineCyclizine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclizine.
MilnacipranThe risk or severity of adverse effects can be increased when Cyclizine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
MirtazapineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyclizine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Cyclizine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclizine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
NabiloneThe risk or severity of adverse effects can be increased when Cyclizine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclizine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyclizine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Cyclizine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cyclizine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclizine.
OlanzapineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclizine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyclizine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cyclizine.
OrphenadrineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cyclizine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyclizine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclizine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyclizine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyclizine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclizine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclizine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyclizine.
ParaldehydeCyclizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Cyclizine.
ParoxetineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclizine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyclizine.
PerampanelThe risk or severity of adverse effects can be increased when Cyclizine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Cyclizine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclizine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclizine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyclizine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Cyclizine.
PhenterminePhentermine may decrease the sedative activities of Cyclizine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cyclizine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyclizine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyclizine.
PipotiazineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pomalidomide.
PramipexoleCyclizine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Cyclizine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyclizine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyclizine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Cyclizine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Cyclizine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cyclizine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclizine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyclizine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cyclizine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyclizine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclizine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Cyclizine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclizine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Cyclizine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyclizine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclizine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclizine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclizine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclizine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclizine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclizine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Cyclizine.
RopiniroleCyclizine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclizine.
RotigotineCyclizine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclizine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyclizine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclizine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclizine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Cyclizine.
SertralineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyclizine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Cyclizine.
StiripentolThe risk or severity of adverse effects can be increased when Cyclizine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclizine.
SuvorexantThe risk or severity of adverse effects can be increased when Cyclizine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclizine.
TetrabenazineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Cyclizine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cyclizine.
ThalidomideCyclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cyclizine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyclizine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyclizine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyclizine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyclizine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Cyclizine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Cyclizine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclizine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyclizine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyclizine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclizine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Cyclizine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclizine.
TrazodoneThe risk or severity of adverse effects can be increased when Cyclizine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclizine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclizine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclizine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclizine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyclizine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cyclizine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Cyclizine.
VilazodoneThe risk or severity of adverse effects can be increased when Cyclizine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Cyclizine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyclizine.
ZiconotideThe risk or severity of adverse effects can be increased when Cyclizine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclizine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Cyclizine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cyclizine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclizine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Cyclizine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Cyclizine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyclizine.
Food Interactions
  • Avoid alcohol.
  • Food may reduce irritation.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Leza JC, Lizasoain I, Lorenzo P: H1- and H2-histamine receptor blockers and opiate analgesia in mice. Methods Find Exp Clin Pharmacol. 1990 Dec;12(10):671-8. [PubMed:1983158 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sulfotransferase activity
Specific Function:
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of estradiol and estrone. May play a role in the regulation of estrogen receptor activity by metabolizing free estradiol. Maximally sulfates beta-estradiol and estrone at concentrations of 20 nM. Also sulfates dehydroepiandrosterone, pregnenolone, ethinylestradiol, equalen...
Gene Name:
SULT1E1
Uniprot ID:
P49888
Molecular Weight:
35126.185 Da
References
  1. Bamforth KJ, Dalgliesh K, Coughtrie MW: Inhibition of human liver steroid sulfotransferase activities by drugs: a novel mechanism of drug toxicity? Eur J Pharmacol. 1992 May 1;228(1):15-21. [PubMed:1397064 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23